¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ°£¾ÏÇÐȸ Á¦14Â÷ Á¤±âÇмú´ëȸ : 2020-02-21

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ°£¾ÏÇÐȸ Á¦14Â÷ Á¤±âÇмú´ëȸ : 2020-02-21
±³À°ÀÏÀÚ : 2020-02-21
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5Ãþ ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : ´ëÇÑ°£¾ÏÇÐȸ Á¦14Â÷ Á¤±âÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑ°£¾ÏÇÐȸ
´ã´çÀÚ : ÀÌÁøÈ­ Â÷Àå
¿¬¶ôó : 02-373-1005  
À̸ÞÀÏ : jhlee@hbni.co.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú      
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í Æò»ýȸ¿ø 4¸¸¿ø, ºñȸ¿ø5¸¸¿ø, Àü°øÀÇ/±ºÀÇ°ü/°£È£»ç 2¸¸¿ø (»çÀüµî·Ï)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 08:30~09:30 Session 1. Plenary Session - Invited Papers  ¹ÌÁ¤(¼ö»óÀÚ ¿¹Á¤)(¹ÌÁ¤) 
È޽Ġ02-21 ±×·£µåº¼·ë 09:30~09:50 È޽Ġ () 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 09:50~10:10 Personalized Risk-based Surveillance for HCC  ÀåÀº¼±(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 10:10~10:30 Surveillance Strategy for HCC Following Curative Intent Treatment  ÇÑ´ëÈÆ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 10:30~10:50 HCC Surveillance Using Imaging Modalities Beyond US  ±è¼Ò¿¬(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 10:50~11:10 Clinical Significance of Tumor Markers in HCC: AFP, PIVKA-II and AFP-L3  ÀÓ¿µ¼®(¿ï»êÀÇ´ë) 
±âŸ 02-21 ±×·£µåº¼·ë 11:10~11:20 ÃÑȸ  () 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 11:20~11:40 Opportunities in Biomaterial for the Treatment of HCC  Dong-Hyun Kim(Northwestern Univ., USA) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 11:40~12:00 Current Clinical Topics of Intrahepatic Cholangiocarcinoma in Japan  Shoji Kubo(President, LCSGJ) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 12:00~13:00 Synergistic Effect of Immune Checkpoint Inhibitor and Anti-angiogenic Agent for HCC Treatment  Ann-Lii Cheng(National Taiwan Univ) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 13:00~14:00 HCC with Oligometastasis at Initial Presentation  ÃÖÁ¾±â&±è°­¸ð (Case), ±è»ó±Õ (³»°ú), ÁÖµ¿Áø (¿Ü°ú), À±»ó¹Î (¹æ»ç¼±Á¾¾çÇаú), ±è°æ¹Î (¿µ»óÀÇÇаú)(¿ï»êÀÇ´ë, ¼øõÇâÀÇ´ë, ¿¬¼¼ÀÇ´ë, ¿ï»êÀÇ´ë, ¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 14:00~14:20 Comparison of Guidelines for Non-invasive Diagnosis of HCC  ÀÌÁ¤¹Î(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 14:20~14:40 Current Evidences and Future Perspectives of Targeted Therapies and Immune Checkpoint Inhibitors  Á¶¼º¹ü(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 14:40~15:00 Recommended and Extended Indications of Surgical Resection for HCC  ÃÖ±Ô¼º(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 15:00~15:20 How To Expand the Role of Radiotherapy in HCC  Á¤ÁøÈ«(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 15:20~16:20 Poster Presentation  Ã¤ÅÃÀÚ ¿Ü() 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 16:20~16:40 Microwave Ablation vs. Radiofrequency Ablation vs. Cryoablation in Early Stage HCC  À̹οì(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 16:40~17:00 Transarterial Radioembolization for HCC: Indications, Patient Selection and Outcomes  ±èÀ±ÁØ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 17:00~17:20 When Do We Select Photon Beam or Particle Beam Radiotherapy?  ¹ÚÈñö(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 17:20~17:40 Stretching the Limits of Laparoscopic Surgery in HCC  ±è±âÈÆ(¿ï»êÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ°£¾ÏÇÐȸ Á¦14Â÷ Á¤±âÇмú´ëȸ : 2020-02-21""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û »ï¼º¼­¿ïº´¿ø GI WINTER SCHOOL 2020 : 2020-02-22
´ÙÀ½±Û ¼¼ºê¶õ½ºº´¿ø À̺ñÀÎÈÄ°ú Á¦14Â÷ ¿¬¼¼ ÄÚ¼ºÇü ÇغνǽÀ : 2020-02-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21000 ºÎ»ê ´ëÇÑÁ·ºÎÁ·°üÀýÇÐȸ - Á¦19Â÷ Çмú´ëȸ : 2024-06-23 0 8 2024-06-17
20999 ¼­¿ï 2024³â 6¿ù ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ ¿¬¼ö°­Á : 2024-06-23 0 9 2024-06-17
20998 ¼­¿ï Á¦ 10ȸ ´ëÇÑ»êºÎÀΰúÃÊÀ½ÆÄÇÐȸ ¼­¿ïÁöȸ ¿¬¼ö°­Á : 2024-06-23 0 6 2024-06-17
20997 ¼­¿ï ´ëÇѵÎÅëÇÐȸ 2024³â Ãá°èÇмú´ëȸ : 2024-06-23 0 10 2024-06-17
20996 ´ë±¸ 2024³â ´ëÇѼÒÈ­±âÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö°­Á : 2024-06-23 0 10 2024-06-17
20995 °æ±â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ °æÀÎÁöȸ Á¦7ȸ °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-23 0 34 2024-06-16
20994 ¼­¿ï Á¦18ȸ ´ëÇѺñ°úÇÐȸ ½ÉÆ÷Áö¾ö : 2024-06-23 0 19 2024-06-16
20993 ÀÎõ ÀÎÇÏ´ëÇб³º´¿ø Á¦6ȸ ÀÎÇÏÇǺνÉÆ÷Áö¾ö : 2024-06-22 0 10 2024-06-16
20992 ¼­¿ï Á¦23ȸ Çѱ¹Á¤¸Æ°æÀ念¾çÇÐȸ Çмú´ëȸ ¹× 2024 ±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2024-06-22 0 10 2024-06-16
20991 ¼­¿ï 2024³â Á¦2Â÷ ´ëÇѳëÀÎÀÇÇÐ ¼¼ºÎÀü¹®ÀÇ ¿¬¼ö°­Á : 2024-06-22 0 15 2024-06-16
20990 ¼­¿ï ´ëÇѼҾÆÀçÈ°¹ß´ÞÀÇÇÐȸ Çмú´ëȸ : 2024-06-22 0 13 2024-06-16
20989 °æ±â 2024³â ¾È¾ç½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-22 0 4 2024-06-16
20988 ¼­¿ï ´ëÇѼҾƳ»ºÐºñÇÐȸ Á¦18Â÷ ºÐ°úÀü¹®ÀÇ ¿¬¼ö°­Á : 2024-06-22 0 7 2024-06-16
20987 ¼­¿ï 2024³â Çѱ¹ºÐ¼®½É¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-22 0 6 2024-06-16
20986 ¼­¿ï 2024 ´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ ³ú½Å°æÁ¶Àý Moving Symposium : 2024-06-22 0 5 2024-06-16
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷